Targeting IL-6 by engineered Lactococcus lactis via surface-displayed affibody
Abstract Background Dysregulated production of interleukin (IL)-6 is implicated in the pathology of inflammatory bowel disease (IBD). Neutralization of IL-6 in the gut by safe probiotic bacteria may help alleviate intestinal inflammation. Here, we developed Lactococcus lactis with potent and selecti...
Gorde:
| Egile Nagusiak: | , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BMC
2022-07-01
|
| Saila: | Microbial Cell Factories |
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.1186/s12934-022-01873-7 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|